Buy Crypto
Markets
Spot
FuturesANT
Earn
Event Center
Rewards Hub
More
100%+ PoR
The Dow Jones Industrial Average fell 561.25 points, or 1.11%, to 50,198.17 on November 18, 2026, while the Nasdaq Composite gained 0.42% to 24,429.88. The 1.53-percentage-point divergence was driven The Dow Jones Industrial Average fell 561.25 points, or 1.11%, to 50,198.17 on November 18, 2026, while the Nasdaq Composite gained 0.42% to 24,429.88. The 1.53-percentage-point divergence was driven

Why Is the Dow Down 1.11% While Nasdaq Is Up? UnitedHealth Falls 10%

The Dow Jones Industrial Average fell 561.25 points, or 1.11%, to 50,198.17 on November 18, 2026, while the Nasdaq Composite gained 0.42% to 24,429.88. The 1.53-percentage-point divergence was driven primarily by a sharp selloff in health insurers, particularly UnitedHealth Group (UNH), rather than a uniform decline across the stock market.
UnitedHealth lost 10.21% as investors assessed a new federal proposal to strengthen Medicare Advantage audits and recover improper payments. At the same time, the Nasdaq-100 rose 0.42%, the Russell 2000 advanced 0.46%, and the S&P 500 slipped just 0.23%. The contrasting moves reveal how sector exposure, index weighting and company-specific risks can produce very different market outcomes.
 

Why Did UnitedHealth's Decline Have Such a Large Impact on the Dow?

UnitedHealth closed at $349.91 after falling approximately 10.2%, extending the pressure on health insurance stocks following a November 16 regulatory announcement. Humana and other major health insurers also declined, suggesting that investors were reassessing the sector's potential financial exposure rather than reacting to an isolated company development.
The catalyst was the Centers for Medicare & Medicaid Services' Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH) proposed rule. The proposal would strengthen Medicare Advantage risk-adjustment audits and other program-integrity measures. CMS estimates that the proposed audit approach could recover approximately $9 billion in Medicare Advantage overpayments per payment year.
That figure requires careful interpretation. It represents an agency-wide estimate of potentially recoverable payments, not UnitedHealth's expected losses, and the proposed rule has not taken effect. The market reaction reflects uncertainty over future reimbursement, audit exposure and profitability, rather than a confirmed $9 billion expense for any one insurer.
UnitedHealth's influence was amplified by the Dow's construction. According to S&P Dow Jones Indices, the Dow is a price-weighted index of 30 blue-chip companies. A constituent's influence therefore depends on its share price rather than its total market capitalization. Large dollar moves in higher-priced stocks can produce substantial index-point changes, even without equivalent weakness across the broader market.
 

Why Did Nasdaq Rise While the S&P 500 and Dow Fell?

The Nasdaq Composite gained 0.42%, and the Nasdaq-100 finished at 27,116.26, also up 0.42%. Their gains did not reflect a uniform recovery in technology shares. Nvidia declined 2.89% despite reporting strong quarterly earnings, while AMD rose 5.31%, demonstrating that investors were distinguishing between individual companies within the same industry.
The S&P 500, meanwhile, closed at 7,323.63, down 0.23%, marking its fifth consecutive losing session. The Russell 2000's 0.46% gain further complicated the picture: smaller companies generally performed better than the Dow's blue-chip constituents, while the Nasdaq's positive close showed that technology exposure was not automatically a source of weakness.
This distinction matters because the Nasdaq Composite, Nasdaq-100, S&P 100 and Dow are not interchangeable benchmarks. The Nasdaq Composite covers a broad universe of Nasdaq-listed securities, while the Nasdaq-100 focuses on large nonfinancial companies. The S&P 100, tracked by OEF, uses a different constituent selection and weighting methodology from the Dow, which DIA tracks.
An investor looking only at DIA could conclude that large-company stocks experienced a substantial selloff. Comparing DIA with the Nasdaq-focused QQQ and ONEQ, and with the broader SPY and S&P 100-focused OEF, provides a more useful test of whether weakness was concentrated or widespread.
The difference also contrasts with the earlier November selloff, when technology shares were the principal source of market pressure. That episode is documented in MEXC's analysis of the November 5 QQQ decline.
 

Did the Federal Reserve's November 18 Minutes Cause the Selloff?

The Federal Reserve released the minutes of its October 27–28 meeting on November 18. The minutes showed that almost all participants expected further interest-rate increases to be appropriate under their baseline economic outlooks. They also discussed financial stability risks associated with the rapid expansion of AI-related debt and infrastructure investment.
These comments reinforced an already restrictive monetary policy environment. However, the day's market performance does not support attributing the Dow's decline entirely to higher interest-rate expectations. The 10-year Treasury yield actually eased from approximately 5.10% to 5.06%, while the Nasdaq and Russell 2000 finished higher.
That combination suggests a more specific interpretation: healthcare regulation and company-level losses were the clearest sources of the Dow's relative weakness, while monetary policy concerns formed part of the broader market backdrop. The distinction is important because a sector-specific shock and a market-wide repricing of financing costs have different implications.
The Fed's previous policy decision and the market reaction to it are examined separately in MEXC's October 2026 rate decision analysis.
 

What Does the Dow–Nasdaq Divergence Signal for the Next Trading Session?

The November 18 divergence does not establish that investors have permanently rotated away from healthcare and into technology. One trading session cannot distinguish a lasting sector rotation from a temporary reaction to company-specific developments. The more informative test is whether the performance gap persists, whether insurer weakness broadens, and whether the market-capitalization-weighted indexes begin to reflect the same pressure.
Further developments in the CMS rulemaking process will be important for health insurers. For the broader market, the next signals include corporate earnings, the direction of Treasury yields, and whether strength in technology and smaller companies remains broad enough to offset declines elsewhere.
The central finding is that the Dow's 561-point decline overstated the degree of weakness visible in other major indexes. November 18 was a divided market, not a uniform stock market selloff, and the difference is explained more convincingly by regulatory exposure and index construction than by a single macroeconomic narrative.
Data note: Index performance refers to November 18, 2026, regular-session closing values. Regulatory estimates are proposals, not realized company losses. Analysis is based on publicly disclosed information and does not constitute investment advice.
The Dow Jones Industrial Average fell 561.25 points, or 1.11%, to 50,198.17 on November 18, 2026, while the Nasdaq Composite gained 0.42% to 24,429.88. The 1.53-percentage-point divergence was driven primarily by a sharp selloff in health insurers, particularly UnitedHealth Group (UNH), rather than a uniform decline across the stock market.
UnitedHealth lost 10.21% as investors assessed a new federal proposal to strengthen Medicare Advantage audits and recover improper payments. At the same time, the Nasdaq-100 rose 0.42%, the Russell 2000 advanced 0.46%, and the S&P 500 slipped just 0.23%. The contrasting moves reveal how sector exposure, index weighting and company-specific risks can produce very different market outcomes.
 

Why Did UnitedHealth's Decline Have Such a Large Impact on the Dow?

UnitedHealth closed at $349.91 after falling approximately 10.2%, extending the pressure on health insurance stocks following a November 16 regulatory announcement. Humana and other major health insurers also declined, suggesting that investors were reassessing the sector's potential financial exposure rather than reacting to an isolated company development.
The catalyst was the Centers for Medicare & Medicaid Services' Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH) proposed rule. The proposal would strengthen Medicare Advantage risk-adjustment audits and other program-integrity measures. CMS estimates that the proposed audit approach could recover approximately $9 billion in Medicare Advantage overpayments per payment year.
That figure requires careful interpretation. It represents an agency-wide estimate of potentially recoverable payments, not UnitedHealth's expected losses, and the proposed rule has not taken effect. The market reaction reflects uncertainty over future reimbursement, audit exposure and profitability, rather than a confirmed $9 billion expense for any one insurer.
UnitedHealth's influence was amplified by the Dow's construction. According to S&P Dow Jones Indices, the Dow is a price-weighted index of 30 blue-chip companies. A constituent's influence therefore depends on its share price rather than its total market capitalization. Large dollar moves in higher-priced stocks can produce substantial index-point changes, even without equivalent weakness across the broader market.
 

Why Did Nasdaq Rise While the S&P 500 and Dow Fell?

The Nasdaq Composite gained 0.42%, and the Nasdaq-100 finished at 27,116.26, also up 0.42%. Their gains did not reflect a uniform recovery in technology shares. Nvidia declined 2.89% despite reporting strong quarterly earnings, while AMD rose 5.31%, demonstrating that investors were distinguishing between individual companies within the same industry.
The S&P 500, meanwhile, closed at 7,323.63, down 0.23%, marking its fifth consecutive losing session. The Russell 2000's 0.46% gain further complicated the picture: smaller companies generally performed better than the Dow's blue-chip constituents, while the Nasdaq's positive close showed that technology exposure was not automatically a source of weakness.
This distinction matters because the Nasdaq Composite, Nasdaq-100, S&P 100 and Dow are not interchangeable benchmarks. The Nasdaq Composite covers a broad universe of Nasdaq-listed securities, while the Nasdaq-100 focuses on large nonfinancial companies. The S&P 100, tracked by OEF, uses a different constituent selection and weighting methodology from the Dow, which DIA tracks.
An investor looking only at DIA could conclude that large-company stocks experienced a substantial selloff. Comparing DIA with the Nasdaq-focused QQQ and ONEQ, and with the broader SPY and S&P 100-focused OEF, provides a more useful test of whether weakness was concentrated or widespread.
The difference also contrasts with the earlier November selloff, when technology shares were the principal source of market pressure. That episode is documented in MEXC's analysis of the November 5 QQQ decline.
 

Did the Federal Reserve's November 18 Minutes Cause the Selloff?

The Federal Reserve released the minutes of its October 27–28 meeting on November 18. The minutes showed that almost all participants expected further interest-rate increases to be appropriate under their baseline economic outlooks. They also discussed financial stability risks associated with the rapid expansion of AI-related debt and infrastructure investment.
These comments reinforced an already restrictive monetary policy environment. However, the day's market performance does not support attributing the Dow's decline entirely to higher interest-rate expectations. The 10-year Treasury yield actually eased from approximately 5.10% to 5.06%, while the Nasdaq and Russell 2000 finished higher.
That combination suggests a more specific interpretation: healthcare regulation and company-level losses were the clearest sources of the Dow's relative weakness, while monetary policy concerns formed part of the broader market backdrop. The distinction is important because a sector-specific shock and a market-wide repricing of financing costs have different implications.
The Fed's previous policy decision and the market reaction to it are examined separately in MEXC's October 2026 rate decision analysis.
 

What Does the Dow–Nasdaq Divergence Signal for the Next Trading Session?

The November 18 divergence does not establish that investors have permanently rotated away from healthcare and into technology. One trading session cannot distinguish a lasting sector rotation from a temporary reaction to company-specific developments. The more informative test is whether the performance gap persists, whether insurer weakness broadens, and whether the market-capitalization-weighted indexes begin to reflect the same pressure.
Further developments in the CMS rulemaking process will be important for health insurers. For the broader market, the next signals include corporate earnings, the direction of Treasury yields, and whether strength in technology and smaller companies remains broad enough to offset declines elsewhere.
The central finding is that the Dow's 561-point decline overstated the degree of weakness visible in other major indexes. November 18 was a divided market, not a uniform stock market selloff, and the difference is explained more convincingly by regulatory exposure and index construction than by a single macroeconomic narrative.
Data note: Index performance refers to November 18, 2026, regular-session closing values. Regulatory estimates are proposals, not realized company losses. Analysis is based on publicly disclosed information and does not constitute investment advice.
Market Opportunity
4 Logo
4 Price(4)
$0.00883
$0.00883$0.00883
USD

The articles shared on this page are sourced from public platforms and are provided for reference only. They do not represent the position or views of MEXC. All rights belong to MEXC Editorial Team. If you believe any content infringes upon the rights of a third party, please contact service@support.mexc.com for prompt removal. MEXC does not guarantee the accuracy, completeness, or timeliness of any content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be interpreted as a recommendation or endorsement by MEXC. For expert insights and in-depth analysis, visit MEXC Learn.